Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIDGE-TH1
- Development stage
- Discontinued
- Lead developer
- Mologen
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
MIDGE-TH1 is a proprietary linear DNA vector technology developed by Mologen AG. Unlike traditional circular plasmids, MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors are small, linear, double-stranded DNA molecules sealed with hairpin loops at both ends. This minimalistic design excludes unnecessary bacterial sequences, such as antibiotic resistance genes, which improves safety and reduces the risk of horizontal gene transfer. The TH1 designation indicates that the vector is specifically designed to induce a strong Th1-type immune response, characterized by the activation of cytotoxic T cells and the production of pro-inflammatory cytokines like interferon-gamma. This technology has been primarily investigated as a vaccine platform for infectious diseases, most notably leishmaniasis, and as an immunotherapeutic approach in oncology.
- Other names
- Minimalistic Immunogenically Defined Gene Expression vectorMIDGE vector
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on MIDGE-TH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIDGE-TH1.